Literature DB >> 9679223

A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination.

P Veng-Pedersen1, J A Widness, J Wang, R L Schmidt.   

Abstract

A drug tracer is most commonly applied to get information about the pharmacokinetics (PK) of a drug that is not confounded by an endogenously produced drug or an unknown drug input. An equally important use of tracers that has not been fully recognized is their use in the study of nonlinear PK behavior. In the present study a system analysis is applied to examine the interaction between drug molecules characteristic and intrinsic to any nonlinear process which enables the nonlinearity to be identified and modeled using a drug tracer. The proposed Tracer Interaction Methodology (TIM) forms a general developmental framework for novel methods for examining nonlinear phenomena. Such methods are potentially much more sensitive and accurate than previous methods not exploiting the tracer principle. The methodology proposed is demonstrated in a simulation study and with real data in a specific implementation aimed at determining the Michaelis-Menten (MM) parameters of nonlinear drug elimination while accounting for drug distribution effects. The simulation study establishes that the TIM-based, MM parameter evaluation produces substantially more accurate parameter estimates than a nontracer (NT) conventional method. In test simulations the accuracy of the TIM was in many cases an order of magnitude better than the NT method without evidence of bias. The TIM-based, MM parameter estimation methodology proposed is ideally suitable for dynamic, non-steady-state conditions. Thus, it offers greater applicability and avoids the many problems specific to steady state evaluations previously proposed. TIM is demonstrated in an evaluation of the nonlinear elimination behavior of erythropoietin, a process that likely takes place via receptor-based endocytosis. Due to its high sensitivity, accuracy, and intrinsic nonlinearity the TIM may be suitable for in-vivo studies of receptor binding of the many biotechnology produced peptide drugs and endogenous compounds displaying receptor-mediated elimination.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9679223     DOI: 10.1023/a:1025765330455

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  39 in total

1.  Observations on the physiology of erythropoietin and its role in the regulation of red cell production.

Authors:  F STOHLMAN
Journal:  Ann N Y Acad Sci       Date:  1959-06-25       Impact factor: 5.691

2.  Serum erythropoietin level: relationships to blood hemoglobin concentration and erythrocytic activity of the bone marrow.

Authors:  W Jelkmann; G Wiedemann
Journal:  Klin Wochenschr       Date:  1990-04-17

3.  Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors:  N Gerber; J G Wagner
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-05

4.  In vivo 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep.

Authors:  J A Widness; P Veng-Pedersen; R L Schmidt; L S Lowe; J A Kisthard; C Peters
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

5.  The deterministic identifiability of nonlinear pharmacokinetic models.

Authors:  K R Godfrey; W R Fitch
Journal:  J Pharmacokinet Biopharm       Date:  1984-04

6.  Blood ethanol concentrations during and following constant-rate intravenous infusion of alcohol.

Authors:  P K Wilkinson; A J Sedman; E Sakmar; R H Earhart; D J Weidler; J G Wagner
Journal:  Clin Pharmacol Ther       Date:  1976-02       Impact factor: 6.875

7.  Diphenylhydantoin elimination kinetics in overdosed children.

Authors:  L K Garrettson; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

8.  Decline of erythropoietin formation at continuous hypoxia is not due to feedback inhibition.

Authors:  K U Eckardt; J Dittmer; R Neumann; C Bauer; A Kurtz
Journal:  Am J Physiol       Date:  1990-05

9.  Serum erythropoietin (EST) titers in anemia.

Authors:  G de Klerk; P C Rosengarten; R J Vet; R Goudsmit
Journal:  Blood       Date:  1981-12       Impact factor: 22.113

10.  Erythropoietin in aplastic anemia.

Authors:  V Pavlovic-Kentera; P Milenkovic; R Ruvidic; V Jovanovic; L Biljanovic-Paunovic
Journal:  Blut       Date:  1979-11
View more
  7 in total

1.  Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep.

Authors:  Mohammed H El-Komy; Robert L Schmidt; John A Widness; Peter Veng-Pedersen
Journal:  Biopharm Drug Dispos       Date:  2011-06-15       Impact factor: 1.627

2.  Pharmacokinetic analysis of continuous erythropoietin receptor activator disposition in adult sheep using a target-mediated, physiologic recirculation model and a tracer interaction methodology.

Authors:  Mohammed H El-Komy; John A Widness; Peter Veng-Pedersen
Journal:  Drug Metab Dispos       Date:  2011-01-05       Impact factor: 3.922

3.  Increased erythropoietin elimination in fetal sheep following chronic phlebotomy.

Authors:  Kevin J Freise; John A Widness; Jeffrey L Segar; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pharm Res       Date:  2007-04-25       Impact factor: 4.200

4.  Recombinant human erythropoietin for the treatment of renal anaemia in children: no justification for bodyweight-adjusted dosage.

Authors:  Ruediger E Port; Daniela Kiepe; Michael Van Guilder; Roger W Jelliffe; Otto Mehls
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 5.  Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.

Authors:  Guohua An
Journal:  J Clin Pharmacol       Date:  2019-12-02       Impact factor: 3.126

6.  Simultaneous Target-Mediated Drug Disposition Model for Two Small-Molecule Compounds Competing for Their Pharmacological Target: Soluble Epoxide Hydrolase.

Authors:  Nan Wu; Bruce D Hammock; Kin Sing Stephen Lee; Guohua An
Journal:  J Pharmacol Exp Ther       Date:  2020-04-01       Impact factor: 4.030

7.  Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO).

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.